control and new methodologies that can be applied to product characterization and is interested in exploring with the public and industry whether biological/ biotechnology pharmaceutical products can be well characterized. FDA intends to develop a definition for well characterized biological/biotechnology pharmaceutical products manufactured using biotechnology.

The goals of this meeting are to: (1) Discuss those analytical techniques, process validations, and parameters that are critical in the characterization of biological/biotechnology pharmaceutical products to assure safety, identity, purity, potency, quality, and consistency; and (2) develop a functional definition for well characterized biological/biotechnology pharmaceutical products. The

information generated at the workshop may be used by FDA in developing future scientific and regulatory policies.

Dated: October 20, 1995.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 95–26500 Filed 10–24–95; 8:45 am]

BILLING CODE 4160-01-F

Health Resources and Services Administration

Agency Forms Undergoing Paperwork Reduction Act Review

Periodically, the Health Resources and Services Administration (HRSA) publishes a list of information collection requests under review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the HRSA Reports Clearance Office on (301)–443–1129.

The following request has been submitted to the Office of Management and Budget for review:

1. Data Collection and Reporting Requirements for Healthy Start— Extension and Revision—Patient records and aggregate data are being collected from Healthy Start grantees in order to evaluate the overall effectiveness of the initiative and the value of specific interventions for varying groups of target women. A number of minor revisions have been proposed based on consultations with grantees regarding availability and utility of the data. Burden estimates are as follows:

Type of report	No. of re- spond- ents	Re- sponses per re- spondent	Average burden per re- sponse (hrs)	Total bur- den hours
Patient Data	15	4	80	4,800
	15	1	5	75
	15	1	40	600

Estimated Total Annual Burden: 5,475 hours.

Written comments and recommendations concerning the proposed information collections should be sent within 30 days of this notice to: Allison Eydt, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, DC 20503.

Dated: October 20, 1995.

J. Henry Montes,

Associate Administrator for Policy Coordination.

[FR Doc. 95-26496 Filed 10-24-95; 8:45 am] BILLING CODE 4160-15-P

National Institutes of Health

National Cancer Institutes; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings of the National Cancer Institutes Initial Review Group:

Agenda/Purpose: To review and evaluate grant applications.

Committee Name: Subcommittee F—Manpower and Training.

Date: November 8–10, 1995.

Time: 8 a.m.

Place: The Holiday Inn Georgetown, 2101 Wisconsin Ave., N.W., Washington, D.C. 20007

Contact Person: Mary Bell, Ph.D., 6130 Executive Blvd., Room 611A, Bethesda, MD 20892, Telephone: 301–496–7978.

Committee Name: Subcommittee G—Education

Date: November 14–15, 1995.

Time: 8 a.m.

Place: The Holiday Inn Georgetown, 2101 Wisconsin Ave., N.W., Washington, D.C. 20007.

Contact Person: Neil B. West, Ph.D., 6130 Executive Blvd., Room 611D, Bethesda, MD 20892, Telephone: 301–402–2785.

Committee Name: Subcommittee C—Basic and Preclinical.

Date: December 4-6, 1995.

Time: December 4–7:30 p.m., December 5–6, 1995, 8 a.m.

Place: Ramada Inn, 8400 Wisconsin Ave., Bethesda, MD 20814.

Contact Person: Virginia Wray, Ph.D., 6130 Executive Plaza, Room 635D, Bethesda, MD 20892, Telephone: 301–496–9236.

Committee Name: Subcommittee B—Comprehensive.

Date: December 7-8, 1995.

Time: 8:30 a.m.

Place: Ramada Inn, 8400 Wisconsin Ave., Bethesda, MD 20814.

Contact Person: Dr. David E. Maslow, 6130 Executive Blvd., Room 643A, Bethesda, MD 20892, (301) 496–2330.

The meetings will be closed in accordance with the provisions set forth in sec. 552b(c)(4) and 552(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade

secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which could constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control.)

Dated: October 18, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–26384 Filed 10–24–95; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings of the National Cancer Institute Special Emphasis Panel (SEP):

Name of SEP: Developmental Therapeutics.

Date: November, 13. 1995.

Time: 9 a.m.

Place: 6130 Executive Blvd., Conference Room F, Rockville, MD 20852.

Contact Person: Lalita Palekar, Ph.D., Scientific Review Administrator, National Cancer Institute, 6130 Executive Blvd., Room 609, Rockville, MD 20852, (301) 496–7575.

Purpose/Agenda: This meeting will be devoted to the review, discussion, and evaluation of individual contract proposals.

Name of SEP: Small Business Innovation Research Program.

Date: November 15, 1995.

Time: 1:30 p.m.

Place: 6130 Executive Blvd., Room 609, Rockville, MD 20852.

Contact Person: Courtney Michael Kerwin, Ph.D., Scientific Review Administrator, National Cancer Institute, 6130 Executive Blvd., Room 609, Rockville, MD 20852.

Purpose/Agenda: Grant Teleconference.

Name of SEP: Epidemiology.

Date: November 7, 1995.

Time: 9 a.m.

Place: 6130 Executive Blvd., Conference Room J, Rockville, MD 20852.

Contact Person: Courtney Michael Kerwin, PH.D., Scientific Review Administrator, National Cancer Institute, 6130 Executive Blvd., Room 609, Rockville, MD 20852, (301) 496–7421.

Purpose/Agenda: Review of Contract Proposals.

The meetings will be closed in accordance with the provisions set forth in sec. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395; Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower, 93.399, Cancer Control.)

Dated: October 18, 1995.

Susan K. Feldman,

Committee Management Officer, NIH. [FR Doc. 95–26383 Filed 10–24–95; 8:45 am]

BILLING CODE 4140-01-M

National Institute on Deafness and Other Communication Disorders; Notice of a Meeting of the Research Priorities Subcommittee of the NDCD Advisory Council

Notice is hereby given of the meeting of the Research Priorities Subcommittee of the NDCD Advisory Council on October 31, 1995. The meeting will take place from 1 to 3 pm as a telephone conference call in Conference Room 7, Building 31C, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892.

The meeting, which is open to the public, will be held to discuss new research priorities in the areas of deafness and communication disorders.

Attendance by the public is limited to space available.

Summaries of the meeting and a roster of members may be obtained from Dr. Earleen Elkins, Acting Director, Division of Extramural Activities, NIDCD, Executive Plaza South, Room 400C, 6120 Executive Blvd., Bethesda, Maryland 20892, 301–496–8693, upon request.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Dr. Elkins in advance of the meeting.

Due to an administrative error, this Federal Register notice is being published less than 15 days before the meeting date.

(Catalog of Federal Domestic Assistance Program No. 93.173 Biological Research Related to Deafness and Communication Disorders)

Dated: October 20, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.
[FR Doc. 95–26531 Filed 10–20–95; 4:03 am]
BILLING CODE 4140–01–M

National Heart, Lung, and Blood Institute; Notice of a Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meeting:

Name of SEP: Research Career Development Awards (K02) and Mentored Clinical Scientist Development Awards (K08).

Date: November 29-30, 1995.

Time: 7:30 p.m.

Place: Ramada Inn at Congressional Plaza, Rockville, Maryland.

Contact Person: S. Charles Selden, Ph.D., Rockledge II, Room 7196, Bethesda, Maryland 20892–7924, (301) 435–0288.

Purpose/Agenda: To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institute of Health.)

Dated: October 18, 1995.

Susan K. Feldman,

Committee Management Officer, NIH. [FR Doc. 95–26388 Filed 10–24–95; 8:45 am]

BILLING CODE 4140-01-M

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Initial Review Group (IRG) meeting:

Name of IRG: Heart, Lung, and Blood Program Project Review Committee.

Date: November 30, 1995.

Time: 8:00 a.m.

Place: Holiday Inn Chevy Chase, Chevy Chase, Maryland.

Contact Person: Dr. Jeffrey H. Hurst, 6701 Rockledge Drive, Rm. 7208, Bethesda, Maryland 20892, (301) 435–0303.

Purpose/Agenda: To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institute of Health.)

Dated: October 18, 1995.

Susan K. Feldman,

Committee Management Officer, NIH. [FR Doc. 95–26387 Filed 10–24–95; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Mental Health; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the Board of Scientific Counselors, National Institute of Mental Health, for November 1995.

In accordance with the provisions set forth in section 552b(c)(6), Title 5, U.S.C. and section 10(d) of Pub. L. 92–463, the entire meeting will be closed for the review, discussion, and evaluation of staff scientists and individual programs and projects. The subject matter to be reviewed contains information of a confidential nature, including consideration of personnel qualifications and performance, the